• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Oscar Health (OSCR) Is Down 10.6% After Swinging to Q2 Profit and Raising 2026 Guidance

    Simply Wall St·08/09/2026 04:39:03
    Listen to the news
    • Oscar Health, Inc. reported a sharp turnaround in past second-quarter 2026 results, moving from a net loss to net income of US$361.81 million and lifting basic earnings per share from continuing operations to US$1.20 from a loss per share of US$0.89 a year earlier.
    • Over the first half of 2026, Oscar Health generated US$1.04 billions in net income and significantly higher earnings per share, while also highlighting technology and AI initiatives that are helping improve efficiency and margins.
    • We’ll now examine how this move to profitability and raised full-year earnings guidance could reshape Oscar Health’s broader investment narrative.

    The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Oscar Health Investment Narrative Recap

    To own Oscar Health, you need to believe its technology focused, ACA centric model can stay profitable while controlling medical costs and regulatory complexity. The latest move to over US$1.0 billion in first half net income and raised 2026 earnings guidance directly reinforces the near term catalyst of sustained profitability, while the biggest risk remains whether these results can hold up if medical loss ratios or policy conditions become less favorable.

    The most relevant recent announcement is Oscar’s higher 2026 operating earnings guidance to US$500 million to US$700 million on US$18.7 billion to US$19.0 billion in revenue. This ties the profitability story to concrete near term financial targets and puts more focus on execution: keeping technology and AI driven efficiency gains intact, while managing growth in ACA and ICHRA membership without letting claims volatility erode the improved margins investors are now watching closely.

    Yet behind these strong numbers, investors should be aware of growing concerns around long term regulatory shifts and rising medical costs that could...

    Read the full narrative on Oscar Health (it's free!)

    Oscar Health's narrative projects $23.8 billion revenue and $998.5 million earnings by 2029. This requires 21.4% yearly revenue growth and a $1,037.9 million earnings increase from -$39.4 million today.

    Uncover how Oscar Health's forecasts yield a $24.20 fair value, a 13% downside to its current price.

    Exploring Other Perspectives

    OSCR 1-Year Stock Price Chart
    OSCR 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming Oscar could reach about US$25.9 billion of revenue and roughly US$973 million of earnings, so this profitability surprise may push that bullish AI driven margin expansion story further, even as others still worry that high medical costs and intense competition could limit how far this improvement really goes.

    Explore 11 other fair value estimates on Oscar Health - why the stock might be worth 13% less than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In Oscar Health?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.